TYK2 Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2024

Non-receptor tyrosine-protein kinase TYK2 is an enzyme that in humans is encoded by the TYK2 gene. TYK2 was the first member of the JAK family that was described (the other members are JAK1, JAK2, and JAK3). It has been implicated in IFN-α, IL-6, IL-10, and IL-12 signaling. TYK2 Inhibitors are a class of drugs that target the TYK2 protein. TYK2 is an enzyme that plays a crucial role in the signaling pathways of various immune cells, including those involved in autoimmune and inflammatory diseases. By inhibiting the activity of TYK2, these drugs aim to modulate the immune response and reduce inflammation. TYK2 inhibitors are mainly being developed as potential treatments for autoimmune conditions such as rheumatoid arthritis, psoriasis, diabetes complications, fever, kidney diseases, urologic diseases, and inflammatory bowel disease.

By targeting TYK2, they can interfere with the signaling pathways that contribute to the inflammatory process and help alleviate the symptoms associated with these diseases. According to WHO, arthritis affects millions of people in Europe and the USA, causing significant pain and disability. In Europe, around 60 million people are affected by arthritis, with osteoarthritis and rheumatoid arthritis being the most prevalent types. In the USA, arthritis affects over 54 million adults. Growth drivers such as the Potential for treating autoimmune diseases, increasing prevalence of such conditions, demand for novel therapies, research advancements, and market expansion. Moreover, many leading market players such as BMS launched Sotyktu (Deucravacitinib) tablets for the treatment of plaque psoriasis and many other molecules are under various stages of clinical development.

Key Market Developments:

• In September 2022, BMS received FDA approval for the Sotyktu (Deucravacitinib) tablets for the treatment of adults with moderate-to-severe plaque psoriasis.
• In June 2022, Eli Lilly received an FDA grant for its Olumiant (Baricitinib) for an expanded indication of severe alopecia areata.

Approved Drug Molecules and Brand Names for TYK2 Inhibitors:

 Sotyktu (Deucravacitinib) tablets

Olumiant (Baricitinib)

Rinvoq (Upadacitinib)

Drugs under the Pipeline for TYK2 Inhibitors:

Brepocitinib (PF-06700841)

Izencitinib (TD-1473)

GLPG3667

TLL018

Gusacitinib (ASN002)

Ropsacitinib (PF-06826647)

BMS-986322

ESK-001

VTX958

Brepocitinib Topical Cream (PF-06700841 Topical)

BGB-23339

CPL'116

FTP-637

GLPG-3121

ICP-332

PF-06263276

TAK-279

TD-8236

ICP-488

MAX-40070

OST-122

QY201

TDM-180935

TLL018 Extended Release

Clinical Activity and Developments of TYK2 Inhibitors:

Till July 2023, more than 20 companies have approximately 28 molecules targetting many autoimmune diseases. For these molecules, more than 150 clinical trials are being conducted and the majority are in phase-2, phase-3 clinical trials by the players across the globe. For instance,

• In July 2020, Galapagos completed phase 1, a first-in-human randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of GLPG3667 in adult, healthy, male subjects.